(Q38097339)

28 August 2017

title

Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia (English)

1 reference

28 August 2017

0 references

Rebekah L O'Shea

3

0 references

Michael D Wiese

object named as

Michael D Wiese

series ordinal

2

0 references

Michael J. Sorich

object named as

Michael J Sorich

series ordinal

1

0 references

author name string

Brita Pekarsky

series ordinal

4

1 reference

28 August 2017

publication date

1 May 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

31

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

377-391

1 reference

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Prescription drug spending trends in the United States: looking beyond the turning point

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

The antiplatelet and antithrombotic actions of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Anti-inflammatory effects of statins: clinical evidence and basic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Statins promote potent systemic antioxidant effects through specific inflammatory pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

21 January 2018

Statins personalized.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Transporter pharmacogenetics and statin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Cost-effectiveness analysis of genetic screening for the Taq1B polymorphism in the secondary prevention of coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

The ezetimibe controversy - can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Variation at the cholesteryl ester transfer protein gene in relation to plasma high density lipoproteins cholesterol levels and carotid intima-media thickness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Lack of association of the common TaqIB polymorphism in the cholesteryl ester transfer protein gene with angiographically assessed coronary atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

The -629C>A polymorphism in the CETP gene does not explain the association of TaqIB polymorphism with risk and age of myocardial infarction in Icelandic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqI

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

ACE (I/D) polymorphism and response to treatment in coronary artery disease: a comprehensive database and meta-analysis involving study quality evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

21 January 2018

Adherence to Medication

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Hospital percutaneous coronary intervention appropriateness and in-hospital procedural outcomes: insights from the NCDR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

DNA testing for familial hypercholesterolemia: improving disease recognition and patient care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Replication validity of genetic association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

The thin line between hope and hype in biomarker research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Assessing the cost-effectiveness of pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertensi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Cerivastatin, genetic variants, and the risk of rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

A new method for measurement of total plasma PCSK9: clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

A gene score of nine LDL and HDL regulating genes is associated with fluvastatin-induced cholesterol changes in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Apolipoprotein E epsilon-4 polymorphism is associated with younger age at referral to a lipidology clinic and a poorer response to lipid-lowering therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Use of genotype frequencies in medicated groups to investigate prescribing practice: APOE and statins as a proof of principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

The SLCO1B1*5 genetic variant is associated with statin-induced side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

The microeconomics of personalized medicine: today's challenge and tomorrow's promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0045-6

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study

21 January 2018

1 reference

12 December 2020

Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study

1 reference

12 December 2020

Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin

1 reference

12 December 2020

Genetic variants in haem oxygenase-1 and endothelial nitric oxide synthase influence the extent and evolution of coronary artery atherosclerosis

1 reference

12 December 2020

The Role of a Common Variant of the Cholesteryl Ester Transfer Protein Gene in the Progression of Coronary Atherosclerosis

1 reference

12 December 2020

[Cost-effectiveness analysis of a genetic screening program in the close relatives of Spanish patients with familial hypercholesterolemia]

1 reference

12 December 2020

Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization

1 reference

12 December 2020

The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies

1 reference

12 December 2020

PON1 Q192R and clopidogrel: a case of the winner's curse or inadequate replication?

1 reference

12 December 2020

Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies

1 reference

12 December 2020

10.1007/S40273-013-0045-6

Identifiers

DOI

1 reference

28 August 2017

1 reference